Krystal Biotech, Inc.KRYSNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +879.91% | +116.26% | +94.88% | +36.65% | +16.65% |
| Gross Profit Growth | +825.92% | +128.23% | +94.15% | +38.28% | +19.41% |
| EBITDA Growth | +0.00% | +252.96% | +409.24% | +76.94% | +35.97% |
| Operating Income Growth | +0.00% | +1218.64% | +0.00% | +358.87% | +84.43% |
| Net Income Growth | -66.34% | +423.23% | +3734.01% | +146.23% | +192.00% |
| EPS Growth | -67.01% | +409.68% | +4033.33% | +146.30% | +188.55% |
| EPS Diluted Growth | -67.38% | +406.67% | +3900.00% | +143.40% | +192.34% |
| Weighted Average Shares Growth | +2.40% | +2.08% | +1.84% | +1.09% | +0.83% |
| Weighted Average Shares Diluted Growth | +3.50% | +3.70% | +1.98% | +0.38% | -0.23% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +94.92% | +0.00% | -32.62% |
| Free Cash Flow Growth | +0.00% | +0.00% | +69.30% | +0.00% | -34.35% |
| Receivables Growth | +944.42% | +149.16% | +122.22% | +7.95% | +33.23% |
| Inventory Growth | +252.05% | +279.50% | +171.29% | +154.87% | +102.53% |
| Asset Growth | +24.29% | +29.02% | +25.91% | +24.05% | +26.24% |
| Book Value per Share Growth | +14.43% | +19.06% | +20.98% | +22.71% | +27.40% |
| Debt Growth | -10.14% | -10.29% | +22.38% | +25.94% | +27.22% |
| R&D Expense Growth | +27.11% | +18.94% | +30.10% | -7.53% | -2.41% |
| SG&A Expenses Growth | +21.17% | +34.53% | +25.58% | +27.27% | +30.87% |